Does the CTLA4 rs3087243 (CT60) GG genotype increase autoimmune risk?

The CTLA4 rs3087243 (CT60) polymorphism is a significant genetic variant involved in the regulation of the immune system's "braking" mechanism. While the GG genotype is strongly associated with an increased risk for various autoimmune and immune dysregulation phenotypes, there is nuance in the research regarding its exact mechanistic effect on protein expression.

Clinical and epidemiological evidence

Research consistently identifies the CTLA4 rs3087243 GG genotype as a risk factor for several autoimmune conditions, particularly those involving the thyroid.

• Autoimmune Thyroid Disease (AITD): In pediatric populations with type 1 diabetes, the GG genotype is a potent risk factor for comorbid AITD, such as Graves' disease and hypothyroidism. Studies in European cohorts (e.g., Belarus) have shown that the GG genotype confers a significantly higher risk for Autoimmune Polyglandular Syndrome type 3a (OR 5.06, 95% CI 2.05–12.44) and isolated hypothyroidism (OR 5.30, 95% CI 2.45–11.45) compared to controls.
• Broader Autoimmunity: The association extends across various ethnic groups, including European and Han Chinese populations, where the G allele or GG genotype is frequently linked to a loss of self-tolerance.

Mechanistic explanations

The CTLA-4 protein is an essential immune checkpoint that suppresses T-cell activation. The rs3087243 variant, located in the 3' untranslated region (UTR) of the gene, influences the stability of CTLA-4 mRNA.

• Impact on Expression: There is scientific consensus that this variant is functional, meaning it directly alters protein levels. However, the direction of effect remains a subject of ongoing research. Some evidence suggests the GG genotype results in reduced CTLA-4 expression or function, which impairs the immune system's ability to "turn off" T-cells, leading to the uncontrolled activation characteristic of autoimmunity.
• Alternative Findings: Other mechanistic studies suggest the ancestral G allele may actually be associated with higher levels of soluble CTLA-4 (sCTLA-4) or mRNA stability compared to the A allele. In these models, the A allele is the variant linked to reduced expression and increased T-cell signaling.

Bottom line

The CTLA4 rs3087243 GG genotype is a validated marker for increased risk of autoimmune phenotypes, particularly thyroid-related disorders, with odds ratios frequently exceeding 5.0 in specific populations. While it clearly contributes to immune dysregulation, its role in reducing CTLA-4 expression is supported in many clinical models but countered by some mechanistic studies favoring the A allele as the primary driver of reduced function.